Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jason Stuart Lewis"'
Autor:
John F. Gerecitano, Shanu Modi, Raajit Rampal, Alexander E. Drilon, Matthew G. Fury, Mrinal M. Gounder, James J. Harding, David Michael Hyman, Anna M. Varghese, Martin Henner Voss, Fallon Olga France, Tony Taldone, Erica Gomes DaGama, Mohammad Uddin, Gabriela Chiosis, Jason Stuart Lewis, Serge K. Lyashchenko, Steven M. Larson, Christina Pressl, Mark Dunphy
Publikováno v:
Journal of Clinical Oncology. 33:2537-2537
2537 Background: PU-H71 (PU) is an HSP-90 inhibitor that can be labeled with 124I without altering its biochemical properties. Intratumoral drug concentration can be calculated based on 124I-PU-H71 (*PU) PET imaging, leading to a surrogate marker of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91eb2d478c6938f23e3b47904b5ea9b1
https://doi.org/10.1200/jco.2015.33.15_suppl.2537
https://doi.org/10.1200/jco.2015.33.15_suppl.2537
Autor:
Jarett L. Feldman, Michael J. Morris, Danny F. Martinez, Scott T. Tagawa, David M. Nanus, Stephen Barnett Solomon, Jorge A. Carrasquillo, Victor E. Reuter, Jason Stuart Lewis, Joseph A. O' Donoghue, Susan F. Slovin, Dana E. Rathkopf, Mithat Gonen, Volkan Beylergil, Jeremy C. Durack, Sarah M. Cheal, Neil Harrison Bander, Howard I. Scher, Steven M. Larson, Neeta Pandit-Taskar
Publikováno v:
Journal of Clinical Oncology. 33:164-164
164 Background: There is no standard imaging (SI) modality that specifically and accurately images prostate cancer (PC) metastases, hampering prognostication and response assessment. J591 is a humanized antibody that targets the external domain of PS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70840b31ce3e72d025a8a1f5b18970d9
https://doi.org/10.1200/jco.2015.33.7_suppl.164
https://doi.org/10.1200/jco.2015.33.7_suppl.164
Autor:
Susan F. Slovin, Xiuyan Wang, Melanie Hullings, Gabrielle Arauz, Shirley Bartido, Jason Stuart Lewis, Heiko Schöder, Pat Zanzonico, Howard I. Scher, Michel Sadelain, Isabelle Riviere
Publikováno v:
Journal of Clinical Oncology. 31:72-72
72 Background: A phase I dose-escalating study to assess safety, dose and targeting efficiency of genetically modified autologous human T cells targeted to PSMA was initiated. Preclinical models demonstrated anti-tumor activity and accumulation, migr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8d30d529f31ad0ae35e89ef47589ffc
https://doi.org/10.1200/jco.2013.31.6_suppl.72
https://doi.org/10.1200/jco.2013.31.6_suppl.72